|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administrationDevice
|
auto-injector pen
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
A10BJ05
|
|
gptkbp:CASNumber
|
gptkb:923950-08-7
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:drugClass
|
GLP-1 receptor agonist
|
|
gptkbp:duration
|
long-acting
|
|
gptkbp:form
|
solvent
solution for injection
pre-filled pen
|
|
gptkbp:frequency
|
once weekly
|
|
gptkbp:genericName
|
gptkb:dulaglutide
|
|
gptkbp:halfLife
|
5 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trulicity
|
|
gptkbp:indication
|
gptkb:type_2_diabetes
|
|
gptkbp:KEGGID
|
D10168
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonist
|
|
gptkbp:molecularWeight
|
~63 kDa
|
|
gptkbp:patent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:product
|
recombinant fusion protein
|
|
gptkbp:riskFactor
|
gptkb:thyroid_C-cell_tumors
pancreatitis
hypoglycemia (when used with insulin or sulfonylureas)
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
decreased appetite
|
|
gptkbp:storage
|
refrigerated
2°C to 8°C
|
|
gptkbp:UNII
|
K7Q1JQR04M
|
|
gptkbp:usedFor
|
reducing risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
improving glycemic control
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:bfsLayer
|
5
|